

# DIAGNOSTICS AND THERAPEUTICS FOR AUTISM SPECTRUM DISORDERS: GLOBAL MARKETS



HLC181A  
March 2015

Ufuk Ezer  
*Project Analyst*

ISBN: 1-62296-055-6



**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
INTENDED AUDIENCE	3
SCOPE OF THE STUDY	3
INFORMATION SOURCES AND TECHNOLOGY BENCHMARKING	3
FORECASTING METHODOLOGY	3
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL ASD MARKET, THROUGH 2019 (\$ MILLIONS)</i>	9
<i>SUMMARY FIGURE GLOBAL ASD MARKET, 2013-2019 (\$ MILLIONS)</i>	9
CHAPTER 3 OVERVIEW	11
DEFINITION OF AUTISM	11
BACKGROUND OF AUTISM	11
WHY IS AUTISM A 'SPECTRUM' DISORDER?	12
CORE SYMPTOMS OF ASD	12
NON-CORE SYMPTOMS OF ASD	13
ETIOLOGY OF ASD	13
GENETIC FACTORS	14
NEUROCHEMICAL FACTORS	14
ENVIRONMENTAL FACTORS	15
EPIDEMIOLOGY OF ASD	16
SEX RATIO	16
AGE	16
PREVALENCE	16
HERITABILITY	16
COMORBIDITY	17
<i>TABLE 1 ASD-ASSOCIATED COMORBIDITIES AND THEIR PREVALENCE RATES</i>	18
SUBTYPE	18
SEVERITY	18
STANDARDS FOR THE DIAGNOSIS AND TREATMENT OF ASD	19
SCREENING AND DIAGNOSIS OF ASD	19
PHARMACEUTICAL TREATMENT OF ASD	21
ASD-LABELED PHARMACEUTICALS	21
OFF-LABEL PHARMACEUTICALS	21
Antipsychotics	21
Psychostimulants	22
Antidepressants	22
Antiepileptic Drugs	22
Antihypertensives	22
Sleep Medications	22

<b>TOPIC</b>	<b>PAGE NO.</b>
Antianxiety Medications	22
OPPORTUNITIES IN PHARMACEUTICAL DEVELOPMENT	23
CHAPTER 4 REGULATORY LANDSCAPE	25
<i>TABLE 2 LIST OF PEDIATRIC LABEL REVISIONS FOR APPROVED AND OFF-LABEL DRUGS USED ON ASD POPULATIONS</i>	26
<i>TABLE 3 LIST OF ISSUED SAFETY WARNINGS FOR APPROVED AND OFF-LABEL PHARMACEUTICALS USED ON ASD POPULATIONS</i>	27
<i>TABLE 4 LIST OF DRUGS UNDER PEDIATRIC INVESTIGATION</i>	28
CHAPTER 5 GLOBAL MARKETS	31
<i>TABLE 5 GLOBAL ASD MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	32
<i>FIGURE 1 GLOBAL ASD MARKET BY APPLICATION, 2013-2019 (\$ MILLIONS)</i>	32
THERAPEUTICS MARKET	32
OVERVIEW	32
GLOBAL ASD THERAPEUTICS MARKET BY LABEL INFORMATION	33
<i>TABLE 6 GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, THROUGH 2019 (\$ MILLIONS)</i>	33
<i>FIGURE 2 GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, 2013-2019 (\$ MILLIONS)</i>	33
ASD-labeled Pharmaceuticals	34
Off-label Pharmaceuticals	34
GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS	35
<i>TABLE 7 GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 (\$ MILLIONS)</i>	36
<i>FIGURE 3 GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 (\$ MILLIONS)</i>	36
Antipsychotics	37
<i>TABLE 8 GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)</i>	39
<i>FIGURE 4 GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)</i>	39
Psychostimulants	39
<i>TABLE 9 GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)</i>	40
<i>FIGURE 5 GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)</i>	40
Antidepressants	40
<i>TABLE 10 GLOBAL ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)</i>	41
<i>FIGURE 6 GLOBAL ANTIDEPRESSANTS MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)</i>	41
Antiepileptics	41
<i>TABLE 11 GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)</i>	42
<i>FIGURE 7 GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)</i>	42
Antihypertensives	43
<i>TABLE 12 GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)</i>	44

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 8 GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)</i>	44
Sleep Medications	44
<i>TABLE 13 GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)</i>	45
<i>FIGURE 9 GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)</i>	45
Other	45
<i>TABLE 14 GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)</i>	46
<i>FIGURE 10 GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)</i>	46
Novel Therapeutic Classes	47
<i>TABLE 15 GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)</i>	48
<i>FIGURE 11 GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)</i>	48
GLOBAL ASD THERAPEUTICS MARKET BY INDICATION	49
<i>TABLE 16 GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	49
<i>FIGURE 12 GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, 2013-2019 (\$ MILLIONS)</i>	49
Irritability	50
<i>TABLE 17 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, THROUGH 2019 (\$ MILLIONS)</i>	50
<i>FIGURE 13 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, 2013-2019 (\$ MILLIONS)</i>	50
ADHD	51
<i>TABLE 18 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, THROUGH 2019 (\$ MILLIONS)</i>	51
<i>FIGURE 14 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, 2013-2019 (\$ MILLIONS)</i>	52
Aggression	52
<i>TABLE 19 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, THROUGH 2019 (\$ MILLIONS)</i>	52
<i>FIGURE 15 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, 2013-2019 (\$ MILLIONS)</i>	52
Seizures	53
<i>TABLE 20 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, THROUGH 2019 (\$ MILLIONS)</i>	53
<i>FIGURE 16 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, 2013-2019 (\$ MILLIONS)</i>	53
Anxiety and Mood Disorders	54
<i>TABLE 21 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, THROUGH 2019 (\$ MILLIONS)</i>	54
<i>FIGURE 17 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, 2013-2019 (\$ MILLIONS)</i>	55
Sleeping Disorders	55
<i>TABLE 22 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, THROUGH 2019 (\$ MILLIONS)</i>	55

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 18 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, 2013-2019 (\$ MILLIONS)</i>	55
Extrapyramidal Symptoms	56
<i>TABLE 23 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, THROUGH 2019 (\$ MILLIONS)</i>	56
<i>FIGURE 19 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, 2013-2019 (\$ MILLIONS)</i>	56
ASD (Core Symptoms)	57
<i>TABLE 24 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), THROUGH 2019 (\$ MILLIONS)</i>	58
<i>FIGURE 20 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), 2013-2019 (\$ MILLIONS)</i>	58
GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION	58
<i>TABLE 25 GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, THROUGH 2019 (\$ MILLIONS)</i>	59
<i>FIGURE 21 GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, 2013-2019 (\$ MILLIONS)</i>	59
Dopamine and Serotonin Pathway Targeting Drugs	60
<i>TABLE 26 GLOBAL ASD THERAPEUTICS MARKET FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, THROUGH 2019 (\$ MILLIONS)</i>	61
<i>FIGURE 22 GLOBAL ASD THERAPEUTICS FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, 2013-2019 (\$ MILLIONS)</i>	61
Adrenergic Receptor Targeting Drugs	61
<i>TABLE 27 GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2019 (\$ MILLIONS)</i>	62
<i>FIGURE 23 GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2013-2019 (\$ MILLIONS)</i>	62
GABAA Pathway Targeting Drugs	62
<i>TABLE 28 GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, THROUGH 2019 (\$ MILLIONS)</i>	63
<i>FIGURE 24 GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, 2013-2019 (\$ MILLIONS)</i>	63
Drugs with Other Mechanisms of Action	64
<i>TABLE 29 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, THROUGH 2019 (\$MILLIONS)</i>	65
<i>FIGURE 25 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, 2013-2019 (\$ MILLIONS)</i>	65
Drugs with Novel Mechanisms of Action	65
<i>TABLE 30 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, THROUGH 2019 (\$MILLIONS)</i>	66
<i>FIGURE 26 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, 2013-2019 (\$ MILLIONS)</i>	66
GLOBAL ASD THERAPEUTICS BY COMPANY	67
<i>FIGURE 27 GLOBAL ASD THERAPEUTICS MARKET BY COMPANY, FOR 2014 (%)</i>	67
GLOBAL ASD DIAGNOSTICS MARKET	68
OVERVIEW	68
<i>TABLE 31 GLOBAL ASD DIAGNOSTICS MARKET, THROUGH 2019 (\$ MILLIONS)</i>	68
<i>FIGURE 28 GLOBAL ASD DIAGNOSTICS MARKET, 2013-2019 (\$ MILLIONS)</i>	68
TECHNOLOGIES	69
MARKET	70

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 32 GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, THROUGH 2019 (\$ MILLIONS)</i>	70
<i>FIGURE 29 GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, 2013-2019 (\$ MILLIONS)</i>	70
Low Imbursement Group	71
<i>TABLE 33 GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, THROUGH 2019 (\$ MILLIONS)</i>	72
<i>FIGURE 30 GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, 2013-2019 (\$ MILLIONS)</i>	72
Moderate Imbursement Group	72
<i>TABLE 34 GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, THROUGH 2019 (\$ MILLIONS)</i>	73
<i>FIGURE 31 GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, 2013-2019 (\$ MILLIONS)</i>	73
High Imbursement Group	74
<i>TABLE 35 GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, THROUGH 2019 (\$ MILLIONS)</i>	74
<i>FIGURE 32 GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, 2013-2019 (\$ MILLIONS)</i>	74
CONCLUDING REMARKS	75
GLOBAL ASD MARKET DRIVERS AND RESTRAINTS	75
DRIVERS	75
RESTRAINTS	75
GLOBAL ASD MARKETS BY GEOGRAPHICAL REGION	75
<i>TABLE 36 GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, THROUGH 2019 (\$ MILLIONS)</i>	76
<i>FIGURE 33 GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, 2013-2019 (\$ MILLIONS)</i>	76
CHAPTER 6 MARKETS IN NORTH AMERICA	78
<i>FIGURE 34 ASD PREVALENCE RATES IN NORTH AMERICA, 2000-2013 (PER 10,000 PEOPLE)</i>	78
<i>TABLE 37 NORTH AMERICAN ASD MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	79
<i>FIGURE 35 NORTH AMERICAN ASD MARKET BY APPLICATION, 2013-2019 (\$ MILLIONS)</i>	79
THERAPEUTICS MARKET	80
OVERVIEW	80
<i>TABLE 38 NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019 (\$ MILLIONS)</i>	80
<i>FIGURE 36 NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019 (\$ MILLIONS)</i>	80
ASD THERAPEUTICS MARKETS IN NORTH AMERICA BY THERAPEUTIC CLASS	81
<i>TABLE 39 NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 (\$ THOUSANDS)</i>	82
<i>FIGURE 37 NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 (\$ THOUSANDS)</i>	82
Antipsychotics	83
<i>TABLE 40 NORTH AMERICAN ANTIPSYCHOTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	84

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 38 NORTH AMERICAN ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	84
Psychostimulants	85
<i>TABLE 41 NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	86
<i>FIGURE 39 NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	86
Antidepressants	87
<i>TABLE 42 NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	88
<i>FIGURE 40 NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	88
Antiepileptics	88
<i>TABLE 43 NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	89
<i>FIGURE 41 NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	90
Antihypertensives	90
<i>TABLE 44 NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	91
<i>FIGURE 42 NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	91
Sleep Medications	92
<i>TABLE 45 NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	92
<i>FIGURE 43 NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	92
Other	93
<i>TABLE 46 NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	94
<i>FIGURE 44 NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	94
Novel	95
<i>TABLE 47 NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	95
<i>FIGURE 45 NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	95
NORTH AMERICAN ASD DIAGNOSTICS MARKETS	96
OVERVIEW	96
MARKET	96
FORECAST	97
<i>TABLE 48 NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019 (\$ MILLIONS)</i>	97
<i>FIGURE 46 NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019 (\$ MILLIONS)</i>	97
NORTH AMERICAN ASD MARKET BY COUNTRY	98
<i>TABLE 49 NORTH AMERICAN ASD MARKET BY COUNTRY, THROUGH 2019 (\$ MILLIONS)</i>	98
<i>FIGURE 47 NORTH AMERICAN ASD MARKET BY COUNTRY, 2013-2019 (\$ MILLIONS)</i>	98
CHAPTER 7 MARKETS IN EUROPE	101

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 48 ASD COMBINED PREVALENCE RATES IN EU5 COUNTRIES, 2000 TO 2011 (PER 10,000 PEOPLE)</i>	101
<i>TABLE 50 EU5 ASD MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	102
<i>FIGURE 49 EU5 ASD MARKET BY APPLICATION, 2013-2019 (\$ MILLIONS)</i>	102
THERAPEUTICS MARKET	103
OVERVIEW	103
<i>TABLE 51 EU5 ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019 (\$ MILLIONS)</i>	103
<i>FIGURE 50 EU5 ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019 (\$ MILLIONS)</i>	103
ASD THERAPEUTICS MARKETS IN EU5 BY THERAPEUTIC CLASS	104
<i>TABLE 52 EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 (\$ THOUSANDS)</i>	105
<i>FIGURE 51 EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 (\$ THOUSANDS)</i>	105
Antipsychotics	106
<i>TABLE 53 EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	108
<i>FIGURE 52 EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	108
Psychostimulants	108
<i>TABLE 54 EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	109
<i>FIGURE 53 EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	109
Antidepressants	110
<i>TABLE 55 EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	111
<i>FIGURE 54 EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	111
Antiepileptics	112
<i>TABLE 56 EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	112
<i>FIGURE 55 EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	113
Antihypertensives	113
<i>TABLE 57 EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	114
<i>FIGURE 56 EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	114
Sleep Medications	115
<i>TABLE 58 EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	115
<i>FIGURE 57 EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	115
Other	116
<i>TABLE 59 EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)</i>	117
<i>FIGURE 58 EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)</i>	117
EU5 ASD DIAGNOSTICS MARKETS	118
OVERVIEW	118



TOPIC	PAGE NO.
MARKET	118
FORECAST	118
TABLE 60 EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019 (\$ MILLIONS)	119
FIGURE 59 EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019 (\$ MILLIONS)	119
EU5 ASD MARKET BY COUNTRY	119
TABLE 61 EU5 ASD MARKETS BY COUNTRY, THROUGH 2019 (\$ MILLIONS)	120
FIGURE 60 EU5 ASD MARKETS BY COUNTRY, 2013-2019 (\$ MILLIONS)	120
CHAPTER 8 MARKETS IN JAPAN	122
FIGURE 61 ASD PREVALENCE RATES IN JAPAN, 2000-2013 (PER 10,000 PEOPLE)	122
TABLE 62 JAPANESE ASD MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	123
FIGURE 62 JAPANESE ASD MARKET BY APPLICATION, 2013-2019 (\$ MILLIONS)	123
THERAPEUTICS MARKET	124
OVERVIEW	124
ASD THERAPEUTICS MARKET IN JAPAN BY THERAPEUTIC CLASS	124
TABLE 63 JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 (\$ THOUSANDS)	125
FIGURE 63 JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 (\$ THOUSANDS)	125
Antipsychotics	126
TABLE 64 JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	127
FIGURE 64 JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	127
Psychostimulants	128
TABLE 65 JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	128
FIGURE 65 JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	128
Antidepressants	129
TABLE 66 JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	129
FIGURE 66 JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	129
Antiepileptics	130
TABLE 67 JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	130
FIGURE 67 JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	131
Antihypertensives	131
TABLE 68 JAPANESE ANTIHYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	131
FIGURE 68 JAPANESE ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	131
Sleep Medications	132
TABLE 69 JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	132
FIGURE 69 JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	132

<b>TOPIC</b>	<b>PAGE NO.</b>
Other	133
<i>TABLE 70 JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)</i>	133
<i>FIGURE 70 JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)</i>	134
JAPANESE ASD DIAGNOSTICS MARKET	134
OVERVIEW	134
MARKET	134
FORECAST	135
<i>TABLE 71 JAPANESE ASD DIAGNOSTICS MARKET, THROUGH 2019 (\$ MILLIONS)</i>	135
<i>FIGURE 71 JAPANESE ASD DIAGNOSTICS MARKET, 2013-2019 (\$ MILLIONS)</i>	135
CHAPTER 9 PIPELINE ASSESSMENT	138
OVERVIEW	138
STRATEGIC PIPELINE ASSESSMENT	138
PIPELINE ANALYSIS BY PHASE OF DEVELOPMENT	139
PHASE III CLINICAL PIPELINE	139
<i>TABLE 72 NUMBER OF PHASE III CLINICAL TRIALS BY COUNTRY, 2014</i>	139
PHASE II CLINICAL PIPELINE	140
<i>TABLE 73 NUMBER OF PHASE II CLINICAL TRIALS BY COUNTRY, 2014</i>	140
PHASE I CLINICAL PIPELINE	141
<i>TABLE 74 NUMBER OF PHASE I CLINICAL TRIALS BY COUNTRY, 2014</i>	141
PIPELINE BY MECHANISM OF ACTION	141
<i>TABLE 75 NUMBER OF CLINICAL TRIALS BY MECHANISM OF ACTION, 2014</i>	142
CLINICAL PIPELINE BY INDICATION	142
<i>TABLE 76 NUMBER OF CLINICAL TRIALS BY INDICATION, 2014</i>	143
CLINICAL PIPELINE BY PHENOTYPES OF ASD	143
<i>TABLE 77 NUMBER OF CLINICAL TRIALS BY PHENOTYPES OF ASD BY COUNTRY, 2014</i>	144
TECHNOLOGICAL TRENDS AND ANALYTICAL FRAMEWORK	144
MOST PROSPECTIVE DRUG PROFILES	145
NNZ-2566	145
Overview	145
Efficacy	145
Safety	146
Clinical Study Details	146
Phase I Clinical Trial	146
Phase II Clinical Trial	146
<i>TABLE 78 TARGET DRUG PROFILE: NNZ-2566</i>	147
CM-AT	147
Overview	147
Efficacy	148
Safety	148
Clinical Trial Details	148
Phase III Clinical Trials	148
<i>TABLE 79 TARGET DRUG PROFILE: CM-AT</i>	149
RG-7314	149
Overview	149

<b>TOPIC</b>	<b>PAGE NO.</b>
Efficacy	149
Safety	150
Clinical Trial Details	150
Phase II Clinical Trials	150
Phase I Clinical Trials	150
<i>TABLE 80 TARGET DRUG PROFILE: RG7314</i>	150
LATUDA	151
Overview	151
Efficacy	151
Safety	151
Clinical Trial Details	152
Phase III Clinical Trials	152
<i>TABLE 81 TARGET DRUG PROFILE: LATUDA</i>	152
<b>CHAPTER 10 DIAGNOSTIC TECHNOLOGIES: RECENT DEVELOPMENTS</b>	<b>154</b>
<b>MARKET-ENTRY PRODUCTS</b>	<b>155</b>
<b>ARISK2</b>	<b>155</b>
Description	155
Technology Value Appraisal	155
Technology Validity and Utility	155
Innovation and Reimbursement Strategy	156
Cost/comparative Effectiveness	156
<b>NEXTSTEP</b>	<b>156</b>
Description	156
Technology Value Appraisal	157
Technology Validity and Utility	157
Innovation and Reimbursement Strategy	157
Cost/Comparative Effectiveness	157
<b>COMBISNP</b>	<b>158</b>
Description	158
Technology Value Appraisal	158
Technology Validity and Utility	158
Innovation and Reimbursement Strategy	158
Cost/Comparative Effectiveness	159
<b>DEVACT AND DEVSEEK</b>	<b>159</b>
Description	159
Technology Value Appraisal	159
Technology Validity and Utility	159
Innovation and Reimbursement Strategy	160
Cost/Comparative Effectiveness	160
<b>COMPARATIVE EVALUATION FOR MARKET-ENTRY PRODUCTS</b>	<b>160</b>
<i>TABLE 82 MARKET VALUE ESTIMATES OF FOUR MARKET-ENTRY ASD DIAGNOSTIC PRODUCTS</i>	160
<b>IN THE PIPELINE</b>	<b>161</b>
<b>SDX-002</b>	<b>161</b>
Developmental Phase	161
Technology Value Appraisal	161

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 11 COMPANY PROFILES	164
THERAPEUTICS	164
ABBVIE INC.	164
ALCOBRA LTD.	164
APOTEX INC.	164
ASTRAZENECA PLC.	165
AUTISM THERAPEUTICS	165
AVANIR PHARMACEUTICALS INC.	165
BOEHRINGER INGELHEIM	166
CORONADO BIOSCIENCES, INC.	166
CUREMARK LLC	166
ELI LILLY & CO.	167
F. HOFFMANN-LA ROCHE AG	167
FOREST LABORATORIES INC.	167
GLAXOSMITHKLINE	168
JANSSEN PHARMACEUTICALS INC.	168
MALLINCKRODT PHARMACEUTICALS	169
MARINUS PHARMACEUTICALS INC.	169
NEUREN PHARMACEUTICALS LTD.	169
NOVARTIS PHARMA SERVICES AG	170
OTSUKA PHARMACEUTICALS	170
PFIZER INC.	171
PHARMACIA & UPJOHN LLC	171
SUNOVION PHARMACEUTICALS INC.	171
DIAGNOSTICS	172
AMBRY GENETICS	172
ATHENA DIAGNOSTICS	172
COMBIMATRIX CORP.	172
COURTAGEN LIFE SCIENCES INC.	173
GENEDX	173
INTEGRAGEN	173
LINEAGEN INC.	174
SYNAPDX	174
TRANSGENOMIC INC.	174

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL ASD MARKET, THROUGH 2019 (\$ MILLIONS)	9
TABLE 1 ASD-ASSOCIATED COMORBIDITIES AND THEIR PREVALENCE RATES	18
TABLE 2 LIST OF PEDIATRIC LABEL REVISIONS FOR APPROVED AND OFF-LABEL DRUGS USED ON ASD POPULATIONS	26
TABLE 3 LIST OF ISSUED SAFETY WARNINGS FOR APPROVED AND OFF-LABEL PHARMACEUTICALS USED ON ASD POPULATIONS	27
TABLE 4 LIST OF DRUGS UNDER PEDIATRIC INVESTIGATION	28
TABLE 5 GLOBAL ASD MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	32
TABLE 6 GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, THROUGH 2019 (\$ MILLIONS)	33
TABLE 7 GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 (\$ MILLIONS)	36
TABLE 8 GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)	39
TABLE 9 GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)	40
TABLE 10 GLOBAL ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)	41
TABLE 11 GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)	42
TABLE 12 GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)	44
TABLE 13 GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)	45
TABLE 14 GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)	46
TABLE 15 GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ MILLIONS)	48
TABLE 16 GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	49
TABLE 17 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, THROUGH 2019 (\$ MILLIONS)	50
TABLE 18 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, THROUGH 2019 (\$ MILLIONS)	51
TABLE 19 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, THROUGH 2019 (\$ MILLIONS)	52
TABLE 20 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, THROUGH 2019 (\$ MILLIONS)	53
TABLE 21 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, THROUGH 2019 (\$ MILLIONS)	54
TABLE 22 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, THROUGH 2019 (\$ MILLIONS)	55
TABLE 23 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, THROUGH 2019 (\$ MILLIONS)	56
TABLE 24 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), THROUGH 2019 (\$ MILLIONS)	58
TABLE 25 GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, THROUGH 2019 (\$ MILLIONS)	59
TABLE 26 GLOBAL ASD THERAPEUTICS MARKET FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, THROUGH 2019 (\$ MILLIONS)	61

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 27 GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2019 (\$ MILLIONS)	62
TABLE 28 GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, THROUGH 2019 (\$ MILLIONS)	63
TABLE 29 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, THROUGH 2019 (\$MILLIONS)	65
TABLE 30 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, THROUGH 2019 (\$MILLIONS)	66
TABLE 31 GLOBAL ASD DIAGNOSTICS MARKET, THROUGH 2019 (\$ MILLIONS)	68
TABLE 32 GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, THROUGH 2019 (\$ MILLIONS)	70
TABLE 33 GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, THROUGH 2019 (\$ MILLIONS)	72
TABLE 34 GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, THROUGH 2019 (\$ MILLIONS)	73
TABLE 35 GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, THROUGH 2019 (\$ MILLIONS)	74
TABLE 36 GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, THROUGH 2019 (\$ MILLIONS)	76
TABLE 37 NORTH AMERICAN ASD MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	79
TABLE 38 NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019 (\$ MILLIONS)	80
TABLE 39 NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 (\$ THOUSANDS)	82
TABLE 40 NORTH AMERICAN ANTIPSYCHOTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	84
TABLE 41 NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	86
TABLE 42 NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	88
TABLE 43 NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	89
TABLE 44 NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	91
TABLE 45 NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	92
TABLE 46 NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	94
TABLE 47 NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	95
TABLE 48 NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019 (\$ MILLIONS)	97
TABLE 49 NORTH AMERICAN ASD MARKET BY COUNTRY, THROUGH 2019 (\$ MILLIONS)	98
TABLE 50 EU5 ASD MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	102
TABLE 51 EU5 ASD THERAPEUTICS MARKET BY COUNTRY, THROUGH 2019 (\$ MILLIONS)	103
TABLE 52 EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 (\$ THOUSANDS)	105
TABLE 53 EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	108

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 54 EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	109
TABLE 55 EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	111
TABLE 56 EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	112
TABLE 57 EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	114
TABLE 58 EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	115
TABLE 59 EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, THROUGH 2019 (\$ THOUSANDS)	117
TABLE 60 EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2019 (\$ MILLIONS)	119
TABLE 61 EU5 ASD MARKETS BY COUNTRY, THROUGH 2019 (\$ MILLIONS)	120
TABLE 62 JAPANESE ASD MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	123
TABLE 63 JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, THROUGH 2019 (\$ THOUSANDS)	125
TABLE 64 JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	127
TABLE 65 JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	128
TABLE 66 JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	129
TABLE 67 JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	130
TABLE 68 JAPANESE ANTIHYPERTENSIVE MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	131
TABLE 69 JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	132
TABLE 70 JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, THROUGH 2019 (\$ THOUSANDS)	133
TABLE 71 JAPANESE ASD DIAGNOSTICS MARKET, THROUGH 2019 (\$ MILLIONS)	135
TABLE 72 NUMBER OF PHASE III CLINICAL TRIALS BY COUNTRY, 2014	139
TABLE 73 NUMBER OF PHASE II CLINICAL TRIALS BY COUNTRY, 2014	140
TABLE 74 NUMBER OF PHASE I CLINICAL TRIALS BY COUNTRY, 2014	141
TABLE 75 NUMBER OF CLINICAL TRIALS BY MECHANISM OF ACTION, 2014	142
TABLE 76 NUMBER OF CLINICAL TRIALS BY INDICATION, 2014	143
TABLE 77 NUMBER OF CLINICAL TRIALS BY PHENOTYPES OF ASD BY COUNTRY, 2014	144
TABLE 78 TARGET DRUG PROFILE: NNZ-2566	147
TABLE 79 TARGET DRUG PROFILE: CM-AT	149
TABLE 80 TARGET DRUG PROFILE: RG7314	150
TABLE 81 TARGET DRUG PROFILE: LATUDA	152
TABLE 82 MARKET VALUE ESTIMATES OF FOUR MARKET-ENTRY ASD DIAGNOSTIC PRODUCTS	160

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL ASD MARKET, 2013-2019 (\$ MILLIONS)	9
FIGURE 1 GLOBAL ASD MARKET BY APPLICATION, 2013-2019 (\$ MILLIONS)	32
FIGURE 2 GLOBAL ASD MARKET FOR PHARMACEUTICALS BY LABEL INFORMATION, 2013-2019 (\$ MILLIONS)	33
FIGURE 3 GLOBAL ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 (\$ MILLIONS)	36
FIGURE 4 GLOBAL ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)	39
FIGURE 5 GLOBAL PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)	40
FIGURE 6 GLOBAL ANTIDEPRESSANTS MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)	41
FIGURE 7 GLOBAL ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)	42
FIGURE 8 GLOBAL ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)	44
FIGURE 9 GLOBAL SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)	45
FIGURE 10 GLOBAL OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)	46
FIGURE 11 GLOBAL NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS, 2013-2019 (\$ MILLIONS)	48
FIGURE 12 GLOBAL ASD THERAPEUTICS MARKET BY INDICATION, 2013-2019 (\$ MILLIONS)	49
FIGURE 13 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING IRRITABILITY, 2013-2019 (\$ MILLIONS)	50
FIGURE 14 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ADHD, 2013-2019 (\$ MILLIONS)	52
FIGURE 15 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING AGGRESSION, 2013-2019 (\$ MILLIONS)	52
FIGURE 16 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SEIZURES, 2013-2019 (\$ MILLIONS)	53
FIGURE 17 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ANXIETY/MOOD DISORDERS, 2013-2019 (\$ MILLIONS)	55
FIGURE 18 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING SLEEPING DISORDERS, 2013-2019 (\$ MILLIONS)	55
FIGURE 19 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING EXTRAPYRAMIDAL SYMPTOMS, 2013-2019 (\$ MILLIONS)	56
FIGURE 20 GLOBAL ASD THERAPEUTICS MARKET FOR TREATING ASD (CORE SYMPTOMS), 2013-2019 (\$ MILLIONS)	58
FIGURE 21 GLOBAL ASD THERAPEUTICS MARKET BY MECHANISM OF ACTION, 2013-2019 (\$ MILLIONS)	59
FIGURE 22 GLOBAL ASD THERAPEUTICS FOR DOPAMINE-SEROTONIN PATHWAY TARGETING DRUGS, 2013-2019 (\$ MILLIONS)	61
FIGURE 23 GLOBAL ASD THERAPEUTICS MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2013-2019 (\$ MILLIONS)	62
FIGURE 24 GLOBAL ASD THERAPEUTICS MARKET FOR GABAA PATHWAY TARGETING DRUGS, 2013-2019 (\$ MILLIONS)	63
FIGURE 25 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH OTHER MOA, 2013-2019 (\$ MILLIONS)	65



<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 26 GLOBAL ASD THERAPEUTICS MARKET FOR DRUGS WITH NOVEL MOA, 2013-2019 (\$ MILLIONS)	66
FIGURE 27 GLOBAL ASD THERAPEUTICS MARKET BY COMPANY, FOR 2014 (%)	67
FIGURE 28 GLOBAL ASD DIAGNOSTICS MARKET, 2013-2019 (\$ MILLIONS)	68
FIGURE 29 GLOBAL ASD DIAGNOSTICS MARKET BY ALLOCATED AVERAGE COST PER PATIENT, 2013-2019 (\$ MILLIONS)	70
FIGURE 30 GLOBAL ASD DIAGNOSTICS MARKET FOR LOW IMBURSEMENT GROUP, 2013-2019 (\$ MILLIONS)	72
FIGURE 31 GLOBAL ASD DIAGNOSTICS MARKET FOR MODERATE IMBURSEMENT GROUP, 2013-2019 (\$ MILLIONS)	73
FIGURE 32 GLOBAL ASD DIAGNOSTICS MARKET FOR HIGH IMBURSEMENT GROUP, 2013-2019 (\$ MILLIONS)	74
FIGURE 33 GLOBAL ASD MARKET BY GEOGRAPHICAL REGION, 2013-2019 (\$ MILLIONS)	76
FIGURE 34 ASD PREVALENCE RATES IN NORTH AMERICA, 2000-2013 (PER 10,000 PEOPLE)	78
FIGURE 35 NORTH AMERICAN ASD MARKET BY APPLICATION, 2013-2019 (\$ MILLIONS)	79
FIGURE 36 NORTH AMERICAN ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019 (\$ MILLIONS)	80
FIGURE 37 NORTH AMERICAN ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 (\$ THOUSANDS)	82
FIGURE 38 NORTH AMERICAN ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	84
FIGURE 39 NORTH AMERICAN PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	86
FIGURE 40 NORTH AMERICAN ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	88
FIGURE 41 NORTH AMERICAN ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	90
FIGURE 42 NORTH AMERICAN ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	91
FIGURE 43 NORTH AMERICAN SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	92
FIGURE 44 NORTH AMERICAN OTHER THERAPEUTICS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	94
FIGURE 45 NORTH AMERICAN NOVEL PHARMACEUTICALS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	95
FIGURE 46 NORTH AMERICAN ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019 (\$ MILLIONS)	97
FIGURE 47 NORTH AMERICAN ASD MARKET BY COUNTRY, 2013-2019 (\$ MILLIONS)	98
FIGURE 48 ASD COMBINED PREVALENCE RATES IN EU5 COUNTRIES, 2000 TO 2011 (PER 10,000 PEOPLE)	101
FIGURE 49 EU5 ASD MARKET BY APPLICATION, 2013-2019 (\$ MILLIONS)	102
FIGURE 50 EU5 ASD THERAPEUTICS MARKET BY COUNTRY, 2013-2019 (\$ MILLIONS)	103
FIGURE 51 EU5 ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 (\$ THOUSANDS)	105
FIGURE 52 EU5 ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	108
FIGURE 53 EU5 PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	109

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 54 EU5 ANTIDEPRESSANT MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	111
FIGURE 55 EU5 ANTIEPILEPTIC MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	113
FIGURE 56 EU5 ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	114
FIGURE 57 EU5 SLEEP MEDICATION MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	115
FIGURE 58 EU5 OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS BY COUNTRY, 2013-2019 (\$ THOUSANDS)	117
FIGURE 59 EU5 ASD DIAGNOSTICS MARKET BY COUNTRY, 2013-2019 (\$ MILLIONS)	119
FIGURE 60 EU5 ASD MARKETS BY COUNTRY, 2013-2019 (\$ MILLIONS)	120
FIGURE 61 ASD PREVALENCE RATES IN JAPAN, 2000-2013 (PER 10,000 PEOPLE)	122
FIGURE 62 JAPANESE ASD MARKET BY APPLICATION, 2013-2019 (\$ MILLIONS)	123
FIGURE 63 JAPANESE ASD THERAPEUTICS MARKET BY THERAPEUTIC CLASS, 2013-2019 (\$ THOUSANDS)	125
FIGURE 64 JAPANESE ANTIPSYCHOTIC MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	127
FIGURE 65 JAPANESE PSYCHOSTIMULANT MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	128
FIGURE 66 JAPANESE ANTIDEPRESSANT MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	129
FIGURE 67 JAPANESE ANTIEPILEPTIC MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	131
FIGURE 68 JAPANESE ANTI-HYPERTENSIVE MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	131
FIGURE 69 JAPANESE SLEEP MEDICATION MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	132
FIGURE 70 JAPANESE OTHER THERAPEUTIC CLASS MARKET FOR ASD POPULATIONS, 2013-2019 (\$ THOUSANDS)	134
FIGURE 71 JAPANESE ASD DIAGNOSTICS MARKET, 2013-2019 (\$ MILLIONS)	135